BÜCHLER, Tomáš, Kateřina SIMONOVÁ, Pavel FENCL, Jiří JARKOVSKÝ and Jitka ABRAHÁMOVÁ. Clinical Outcomes of Patients with Nonseminomatous Germ Cell Tumours and Negative Postchemotherapy Positron Emission Tomography. Cancer Investigation. LONDON: INFORMA HEALTHCARE, 2012, vol. 30, No 6, p. 487-492. ISSN 0735-7907. doi:10.3109/07357907.2012.679347.
Other formats:   BibTeX LaTeX RIS
Basic information
Original name Clinical Outcomes of Patients with Nonseminomatous Germ Cell Tumours and Negative Postchemotherapy Positron Emission Tomography
Authors BÜCHLER, Tomáš (703 Slovakia, guarantor), Kateřina SIMONOVÁ (203 Czech Republic), Pavel FENCL (203 Czech Republic), Jiří JARKOVSKÝ (203 Czech Republic, belonging to the institution) and Jitka ABRAHÁMOVÁ (203 Czech Republic).
Edition Cancer Investigation, LONDON, INFORMA HEALTHCARE, 2012, 0735-7907.
Other information
Original language English
Type of outcome Article in a journal
Field of Study 30200 3.2 Clinical medicine
Country of publisher United Kingdom of Great Britain and Northern Ireland
Confidentiality degree is not subject to a state or trade secret
Impact factor Impact factor: 2.238
RIV identification code RIV/00216224:14110/12:00060439
Organization unit Faculty of Medicine
Doi http://dx.doi.org/10.3109/07357907.2012.679347
UT WoS 000304751300006
Keywords in English Positron emission tomography; Germ cell tumour; Testicular cancer; Diagnosis; Relapse
Tags International impact
Changed by Changed by: Soňa Böhmová, učo 232884. Changed: 22. 4. 2013 18:35.
Abstract
Univariate and multivariate analyses were carried out to identify factors associated with the failure of 18-fluorodeoxyglucose positron emission tomography (FDG-PET) to correctly predict relapse-free survival in patients with nonseminomatous germ cell tumours. Ninety-three patients with negative postchemotherapy FDG-PET scan were analyzed in the retrospective study. The FDG-PET result was validated by long-term follow-up and, in some patients, by resection of the residual tumour mass. The negative predictive value of FDG-PET was 81.7%. Higher tumour marker levels and nodal stage at diagnosis, presence of residual mass, and teratoma or teratocarcinoma in the primary histology were associated with FDG-PET failure.
PrintDisplayed: 26. 6. 2022 10:43